StemSmart™ MSC – Fistulising Crohn's Disease
Fistulising Crohn's Disease
Phase 1/2 (Special Access Program)Active
Key Facts
Indication
Fistulising Crohn's Disease
Phase
Phase 1/2 (Special Access Program)
Status
Active
About Neuroscientific Biopharmaceuticals
Australian MSC biotech advancing StemSmart™ therapy for Crohn’s disease and other inflammatory disorders.
View full company profile